Oppenheimer Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $45
Oppenheimer Maintains Outperform on Pliant Therapeutics, Lowers Price Target to $45
Oppenheimer保持對pliant therapeutics的Outperform評級,將價格目標下調至45美元。
Oppenheimer analyst Jeff Jones maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target from $48 to $45.
Oppenheimer分析師Jeff Jones維持對Pliant Therapeutics的跑贏大盤評級,並將價格目標從48美元下調至45美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。